There is a need for more efficacious inactivated influenza vaccines, since current
formulations show suboptimal immunogenicity in at-risk populations, like the elderly. More …

More than 70 bacteria, viruses, parasites, and fungi are serious human pathogens. 1
Vaccines are available against some of these agents and are being developed against …

The need to enhance the immunogenicity of purified subunit antigens has prompted the
development of new adjuvants. The adjuvant emulsion MF59™ has been tested in animals …

Oil-in-water emulsions have been successfully used to increase the efficacy,
immunogenicity, and cross-protection of human vaccines; however, their mechanism of …

The need to enhance the immunogenicity of purified subunit antigens has prompted the
development of several new adjuvants. However, many of these new molecules have …

Virus-like particle (VLP) technology is a promising approach for the construction of novel
vaccines, diagnostic tools, and gene therapy vectors. Initially, VLPs were primarily derived …

The identification of natural adjuvants capable of selectively promoting an efficient immune
response against infectious agents would represent an important advance in immunology …

Importance Human infections with avian influenza A/H7N9 have resulted in high morbidity
and mortality in China. Objective To compare safety and immunogenicity of different doses …

Background Influenza vaccines perform poorly in the elderly with reduced serological
response and vaccine efficacy. We evaluated a novel influenza vaccine consisting of the …

BACKGROUND: Adding adjuvants such as MF59® to influenza vaccines can enhance the
immune response. This analysis evaluated the safety profile of MF59-adjuvanted [(+) MF59] …